The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

Abstract High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, h...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Yongfeng Wu, Jinming Xu, Jiawei Xu, Yiqing Wang, Luming Wang, Wang Lv, Jian Hu
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2020-04-01
سلاسل:	Biomarker Research
الموضوعات:	Tumor mutation burden TMB Age Immune checkpoint inhibitor ICI NSCLC
الوصول للمادة أونلاين:	http://link.springer.com/article/10.1186/s40364-020-00188-2
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!